|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that ATF3 can suppress mutp53 oncogenic function, thereby contributing to tumor suppression in TP53-mutated cancer.
|
24554706 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRPV1 stimulation triggers tumor cell death through the branch of the endoplasmic reticulum stress pathway that is controlled by activating transcription factor-3 (ATF3).
|
22820645 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We show that Atf3 is a tumor-suppressor gene inactivated in human glioblastoma multiforme together with Cbx7 and a few other candidates.
|
23680149 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistent with the growth arrest and pro-apoptotic roles of ATF3, ATF3(-) fibroblasts upon Ras transformation exhibited higher growth rate, produced more colonies in soft agar, and formed larger tumor upon xenograft injection than the ATF3(+/+) counterparts.
|
16469745 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, whether ATF3 contributes to the maintenance of genome stability and tumor suppression remains unknown.
|
28869597 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
From the candidates selected, activating transcription factor-3 (ATF-3), caveolin-1, deleted in liver cancer-1 (DLC-1), and nonmetastatic clone 23 (NM23-H2) were chosen for post hoc functional studies based on their previously reported action as tumor suppressors or apoptosis inducers.
|
15674352 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings indicate that ATF3 functions as a tumor suppressor in HCC through targeting and regulating CYR61.
|
30376856 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL1β, IL6 and iNOS transcripts were up-regulated among external cell signaling factors; nine transcription factors (ATF3, C/EBP, c-Fos, Fos-B, JDP2, JunB, c-Maf, NF-κB, TCF4) showed increased expression and 5 (AP-2, CBP, Elk-1, p53, PEA3) were decreased in tumors with high COX-2.
|
21668942 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Activating transcription factor 3 (ATF3), a stress response transcription factor, is known to have a dichotomous role in tumor cells, acting either as a tumor suppressor or an oncogene in a context-dependent manner.
|
21900211 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based upon piRNA:mRNA sequence complementarity, we identified a panel of tumor suppressor genes (ATF3, BTG1, DUSP1, FAS,NFKBIA, UPP1, SESN2, TP53INP1 and MDX1) as direct targets of piR-1245, and successfully validated an inverse correlation between their expression and piR-1245 in CRC.
|
29382334 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma.
|
25149542 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, control xenograft tumors were significantly more responsive to treatment than ATF3 knockdown xenografts.
|
27196751 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The investigation shows that ATF3 may function as a tumor-inhibiting factor through direct regulatory effects on TAp73beta, suggesting a functional link between ATF3 and TAp73beta.
|
18644986 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ARTD treatment induced the expression of tumor suppressive activating transcription factor 3 and inhibited oncogenic E2F transcription factor 1 expression at the mRNA and protein levels.
|
30205376 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expectedly, the analysis of the DEGs common to all three alterations highlighted a group of BioFunctions that included Cell Proliferation of tumor cell lines (14 DEGs), Invasion of cells (10 DEGs) and Migration of tumour cell lines (10 DEGs), with a common core of 5 genes (ATF3, CDKN1A, GDF15, HBEGF and LCN2) that likely represent downstream effectors of the pro-oncogenic activities of PI3K/AKT signalling.
|
28662101 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Low expression of ATF3 may function as a tumor suppressor during human hepatocellular oncogenesis and targeting ATF3 pathway might be beneficial for anti-HCC therapy.
|
24906227 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Collectively, our results suggest that ATF3 and JDP2 regulate the expression of essential tumor promoting factors expressed by fibroblasts within the tumor microenvironment, and thus restrain tumor growth.
|
30670778 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, the results indicate that ATF3 might promote skin cancer cell proliferation and enhance skin keratinocyte tumor development through inhibiting p53 expression and then activating Stat3 phosphorylation.
|
24460316 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumour xenograft was used to evaluate the effect of ATF3 in vivo.
|
30117642 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ATF3, a member of the 'enlarged' AP-1 family, is selectively induced by calcineurin/NFAT inhibition, both under experimental conditions and in clinically occurring tumours, and increased ATF3 expression accounts for suppression of p53-dependent senescence and enhanced tumorigenic potential.
|
20485437 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results thus support that ATF3 is a tumor suppressor in prostate cancer.
|
26522727 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Under physiological conditions, ATF3 expression is transient and plays a pivotal role in controlling the expression of cell-cycle regulators and tumor suppressor, DNA repair, and apoptosis genes.
|
30144543 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We further demonstrate that the proapoptotic function of ATF3 is mediated through direct transcriptional repression of the prosurvival factor <i>BCL-X<sub>L</sub> (BCL2L1)</i> These findings provided the rationale for dual inhibition of HDAC and BCL-X<sub>L</sub>, which we show strongly cooperate to overcome inherent resistance to HDACi across diverse tumor cell types.<b>Conclusions:</b> These findings explain the heterogeneous responses of tumor cells to HDACi-induced apoptosis and suggest a framework for predicting response and expanding their therapeutic use in multiple cancer types.<i></i>.
|
28611196 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gene expression analysis in tumor adjacent normal (pre-neoplastic) tissue identified several genes involved in proliferation (Fosb, Fos, Ptk6, Esr2, Atf3) and inflammation (Atf3, Saa1, TNF-α) that were downregulated in MthfdS<sup>+/-</sup> males.
|
27597531 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, ATF3 gene copy number is >2 in approximately 80% of the breast tumors examined (N=48) and its protein level is elevated in approximately 50% of the tumors.
|
17952119 |
2008 |